Lonza and Asimov Partner on Scalable Lentiviral Vector Manufacturing for Gene Therapy
- Lonza and Asimov are collaborating to advance lentiviral vector manufacturing using Asimov's LV Edge stable producer cell lines combined with Lonza's process development, scale-up, and GMP capabilities.
- The partnership addresses manufacturability challenges in current multi-plasmid transient transfection methods by developing stable, program-specific manufacturing strategies to improve scalability and batch-to-batch consistency.
- The companies will establish a feasibility-first framework spanning transgene optimization, cell line development, process development, analytics, scale-up, GMP production, and CMC readiness for in vivo and ex vivo lentiviral programs.
Operational Impact
Lonza's expanded lentiviral vector GMP manufacturing capability—integrated with Asimov's stable cell line platform—creates a differentiated offering for gene therapy developers seeking to de-risk manufacturing scale-up and reduce time-to-clinic for in vivo LVV programs.
Source: Contract Pharma Breaking News RSS